Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.60 USD
-0.02 (-1.23%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Actinium Pharmaceuticals, Inc. has a market cap of $50.54M, which represents its share price of $1.62 multiplied by its outstanding shares number of 31.20M. As a small-cap company, ATNM's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ATNM 1.60 -0.02(-1.23%)
Will ATNM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
Other News for ATNM
Actinium Pharmaceuticals (ATNM) Showcases Promising Prostate Cancer Treatment Data
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer ...
Actinium Pharmaceuticals' ATNM-400 shows improved survival in prostate cancer
Promising Preclinical Results for ATNM-400 Drive Buy Rating for Actinium Pharmaceuticals
Actinium Pharma (ATNM) Rating Reaffirmed with Stable Price Target | ATNM Stock News